Auditorium (2F) | Room A (2F) | Room B (2F) | Room C (1F) | Room D (1F) | ||
---|---|---|---|---|---|---|
09:00-09:30 | Opening Ceremony | |||||
09:30-10:50 | Plenary Session 1 State of the Art in Cell Therapy |
|||||
10:50-11:00 | Break | |||||
11:00-12:20 | Plenary Session 2 Alternative Donors |
|||||
12:20-12:30 | Break | |||||
12:30-13:10 | Luncheon Symposium 1 |
Luncheon Symposium 2 |
Luncheon Symposium 3 |
Luncheon Symposium 4 (Room D-1) |
Luncheon Symposium 5 (Room D-2) |
|
13:10-13:20 | Break | |||||
13:20-14:50 | Joint Symposium 1 ASTCT-KSBMT Is HSCT still Relevant in Immunotherapy Era for Lymphoid Malignancies? |
Scientific Session 1 Dealing with Practical Issues of Transplantation in Aplastic Anemia |
Education Session 1 Pathogenesis, Diagnosis, Treatment of Endothelial Damage Syndrome |
Nursing Session 1 (Kor.) |
||
14:50-15:00 | Break | |||||
15:00-16:00 | Oral 1 | Oral 2 | Oral 3 | Oral 4 | ||
16:00-16:10 | Break | |||||
16:10-16:30 | Poster | |||||
16:30-16:40 | Break | |||||
16:40-18:10 | Joint Symposium 2 TSBMT-KSBMT Experiences and Future Perspectives on Transplantation and Cellular Therapy for Multiple Myeloma (16:40-17:40) |
Scientific Session 2 Immunotherapy for Lymphoid Malignancy in the Post-CART Era |
Scientific Session 3 Transplantation Related Immunology |
Education Session 2 Conditioning Regimen in Transplant Setting |
||
18:30- | Welcome Reception (Nurimaru APEC House) |
Auditorium (2F) | Room A (2F) | Room B (2F) | Room C (1F) | Room D (1F) | |
---|---|---|---|---|---|
09:00-10:30 | Scientific Session 4 Divergent Approaches to the Use of Autologous Hematopoietic Stem Cell Transplantation |
Scientific Session 5 GVHD in 2023: From Prediction to Prevention |
Scientific Session 6 New Insights in the Immune Effector Cell Therapies for Multiple Myeloma |
Scientific Session 7 Strategies for Successful Cord Blood Transplantation |
|
10:30-10:40 | Break (10:30-10:50) | Break (10:30-10:50) | |||
10:40-10:50 | Break (10:40-10:50) | Break (10:40-10:50) | |||
10:50-11:30 | Plenary Session 3 HSCT in myeloid |
||||
11:30-12:10 | Presidential Symposium New insights and challenges in managing chronic GVHD |
||||
12:10-12:20 | Break | ||||
12:20-13:00 | Luncheon Symposium 6 |
Luncheon Symposium 7 |
Luncheon Symposium 8 |
Luncheon Symposium 9 |
|
13:00-13:10 | Break | ||||
13:10-14:40 | Joint Symposium 3 EBMT-KSBMT Recent Issues in HSCT and Cellular Therapy for ALL |
Scientific Session 8 Bone Marrow Microenvironment in Hematologic Malignancy |
Education Session 3 Prevention and Management Of Virus Disease in HSCT Patients |
Debate Session 1 & 2 (Kor.) * Simultaneous Korean-English interpreting will be provided |
|
14:40-14:50 | Break (14:40-15:00) | ||||
14:50-15:00 | Break (14:50-15:00) | Break (14:50-15:00) | |||
15:00-16:00 | Oral 5 | Oral 6 | Oral 7 | Oral 8 | |
16:00-16:10 | Break | ||||
16:10-16:30 | Poster | ||||
16:30-16:40 | Break | ||||
16:40-18:10 | Joint Symposium 4 East Asia Collaborative Session Current Status of CAR-T Cell Therapy: Real-World Practice and Clinical Trials |
Scientific Session 9 Finding New Era of Haploidentical HSCT |
Scientific Session 10 Data to Clinic for Better Stem Cell Transplantation |
Education Session 4 Current and Future Direction in Chronic GVHD |
|
18:10-18:20 | |||||
18:45- | Gala Dinner (Paradise Hotel Busan, 2F)) |
Auditorium (2F) | Room A (2F) | Room B (2F) | Room C (1F) | Room D (1F) | |
---|---|---|---|---|---|
07:30-09:00 | KSBMT Business Meeting | ||||
09:00-10:30 | Joint Symposium 5 ISCT-KSBMT Industry-Academia Bridging in Cellular Therapy: Synergies and Challenges |
Scientific Session 11 Pediatric Leukemia: Recent Advances in Treatments |
Scientific Session 12 Optimizing HSCT Outcomes in Patients with High-Risk AML |
||
10:30-10:40 | Break | ||||
10:40-12:20 | Joint Symposium 6 JSTCT-KSBMT Recent Updates on the Management of MDS and JMML |
Scientific Session 13 Recent Advances in Cellular Immunotherapy |
Nursing Session 2 (Kor.) |
||
Break (12:10-12:30) | |||||
12:20-12:30 | Break (12:20-12:30) | ||||
12:30-12:40 | Closing Ceremony | ||||
12:40-13:10 | KSBMT General Assembly |